Tesamorelin Price Australia: What a Research Quote Should Include

What does tesamorelin price Australia actually cover in a research quote?

When laboratories compare tesamorelin price Australia listings, the catalogue milligram figure is a claim about a chemical entity only if identity, salt form and specification are stated. Tesamorelin is described in independent drug-evaluation and chemistry reviews as a synthetic analogue of human growth hormone-releasing factor and, in development literature, as TH9507 (PMID:17086939; PMID:19243281; PMID:21283099; PMID:20554713). That nomenclature corresponds to a 44-residue linear peptide bearing an N-terminal trans-3-hexenoyl modification of the human GHRH sequence, typically isolated as an acetate salt and presented as a lyophilised solid for laboratory work. It is not a short oligopeptide and it is not an unspecified GHRH fragment without a defined N-terminus.

Solid-phase synthesis of a 44-mer, selective N-terminal acylation, resin cleavage and several preparative reversed-phase HPLC cycles set a floor under cost. Crude yield falls as chain length increases because deletion sequences, truncated fragments and incompletely deprotected species accumulate. Preparative cuts that protect main-peak purity discard mass, so isolated milligrams cost more than crude milligrams. Residual trifluoroacetate may remain unless a documented exchange to acetate has been performed, and water remains in the lyophilised cake. Those non-peptide components still sit on the balance if the seller quotes gross weight only.

A research quote should disclose the structural descriptor (tesamorelin / TH9507, N-terminally hexenoylated GHRH(1-44)), salt form, appearance, HPLC purity with method, mass-spectrometric intact mass, and whether milligrams are gross lyophilisate or net peptide. Numerically identical Australian prices are not comparable if one lot is unnamed powder and the other is a batch-linked, identity-confirmed solid. Side-chain protecting-group remnants, methionine-related oxidation products where Met is present in the GHRH sequence, and des-acyl 44-mers are chemically plausible impurities for this analogue class and should be in the related-substance conversation even when they are not named on a short CoA. ClaraScience lists tesamorelin as a research reagent with local stock, tracked dispatch and batch documentation; the price is the price of that specified lot. The supply category is laboratory research use only, not a therapeutic good.

How should HPLC purity and related-substance chromatograms be read against a tesamorelin quote?

Reversed-phase HPLC is the workhorse purity assay for research-grade tesamorelin, but a single area-percent number without a method is not a specification. A 44-residue N-acylated peptide generates a dense related-substance map: deletion sequences, truncated GHRH fragments, diastereomers from racemisation during coupling, incompletely deprotected residues, des-acyl material, and oxidation products at susceptible residues. Many of those species have similar hydrophobicity to the parent chain and can sit under or beside the main peak on a poorly resolving gradient. A certificate of analysis that supports the quoted price therefore records column chemistry (C18 or C4 are typical for this chain length), particle size, gradient programme, flow rate, column temperature, detection wavelength, integration threshold, and the system-suitability outcome for the release sequence.

Detection wavelength is not a trivial detail. Peptide bonds are commonly monitored near 214 nm, where small gradient and solvent-absorbance errors inflate or deflate impurity area-percent. A CoA should state the wavelength and the blank-subtraction practice. Ion-pairing with trifluoroacetic acid versus formic acid changes retention and peak shape for an acylated 44-mer, so the method printed on the CoA must match the method that produced the chromatogram. Diode-array peak-purity assessment can flag spectral heterogeneity under the main peak, but it does not identify impurities and it does not replace mass spectrometry. Related-substance reporting should state the main-peak percentage, the sum of impurities above a defined reporting threshold, and the relative retention times of numbered impurities. Reporting thresholds of 0.10 percent or 0.05 percent change both the impurity count and the apparent purity, and they must be declared before two lots are priced against each other.

Because tesamorelin is treated in the evaluation literature as a defined growth hormone-releasing factor analogue, related-substance work should be analogue-specific rather than a generic short-peptide gradient (PMID:22298602). Laboratory acceptance windows for research material commonly sit at a main-peak area of 95 percent or 98 percent, with individual unspecified impurities capped by an internal SOP. Those windows are reagent specifications, not clinical release criteria. Raising final area-percent requires narrower preparative cuts and reduces isolated yield, which is a direct cost driver. Confirm that the chromatogram belongs to the lyophilised vial lot, not to an in-process fraction or to another batch, before the milligram price is accepted.

Why do mass confirmation and net peptide content change the true milligram cost?

HPLC retention time does not establish tesamorelin identity. Electrospray ionisation mass spectrometry should confirm the intact mass of the N-terminally modified 44-residue chain, usually as a multiply charged ion envelope that deconvolutes to the expected monoisotopic or average mass. A defensible CoA lists observed m/z values, assigned charge states, and the deconvoluted mass with a stated tolerance set by the laboratory SOP. A line that reads only that mass spectrometry is consistent, without values, is not equivalent evidence. Where the laboratory must distinguish tesamorelin from truncated GHRH sequences or from other GHRH analogues held in the same inventory, tandem-MS fragment ions add sequence-level support. Orthogonal identity, meaning chromatographic purity plus intact mass, is the minimum package against which a research price should be judged, consistent with treating tesamorelin as a defined synthetic GHRF analogue rather than as a generic powder (PMID:17086939; PMID:22298602).

Net peptide content is the second variable that rewrites unit-cost comparisons. Lyophilised solids contain counter-ion and residual water. Amino-acid analysis or elemental nitrogen, a counter-ion assay, and Karl Fischer titration convert gross milligrams into peptide milligrams. A vial labelled by gross weight at a high water and acetate load contains less peptide than the label suggests. If two quotes use the same gross milligram price, only the lot with documented net peptide content can be normalised to a true peptide unit cost. Residual trifluoroacetate from cleavage and preparative HPLC can dominate the non-peptide mass if salt exchange to acetate has not been verified. Ion-chromatography or a validated HPLC counter-ion method should name the anion and report it as mass percent or as a molar ratio. A quote that specifies acetate, reports trifluoroacetate below a limit, and gives water content is pricing a characterised solid; a quote that is silent on salt form is pricing an unknown mixture.

Laboratories should request net peptide content, water and counter-ion with the HPLC and mass-spectrometry package, then divide price by net peptide milligrams. Identity keys used in the analogue literature, namely tesamorelin, TH9507 and synthetic GHRF, should appear on the CoA so that the solid can be reconciled to the same chemical descriptor (PMID:19243281; PMID:20554713).

Which certificate-of-analysis fields should be included before you accept an Australian tesamorelin quote?

A research-grade tesamorelin CoA is not an optional attachment; it is part of what the milligram price buys. Minimum fields are product name and structural descriptor, lot or batch number identical to the vial label, test or release date, appearance, HPLC purity with method reference and chromatogram, mass-spectrometric identity with observed mass, specification limits with pass or fail, and the identity of the testing laboratory. Fields that reasonably support a higher quote include a related-substance table, diode-array peak-purity data, counter-ion quantification, Karl Fischer water, residual-solvent results where cleavage or precipitation solvents are relevant, and a laboratory storage statement for the lyophilised solid. Raw chromatographic files, or at least a paginated chromatogram showing integration marks, are more useful in an audit trail than a purity integer copied onto a letterhead.

Traceability has its own cost. The lot number should index retained chromatograms, instrument identifiers, the sequence of system-suitability and sample injections, and a sampling record. Multi-vial orders should share one lot wherever possible so that a single HPLC and mass-spectrometry package covers the campaign. Spreading one analytical package across many vials lowers documentation cost per milligram even when the peptide unit price is unchanged. Mixed lots each require their own release file, which is a genuine extra cost and should appear in the comparison table. Australian laboratories that archive data for internal audit or for later methods papers need method identifiers and integration parameters, not a marketing one-page summary. A second-person review of the chromatogram, where the supplier’s quality system provides it, is a further differentiator between a released lot and an unreviewed print-out.

Regulatory framing belongs on the CoA and the invoice: research use only, not for human or veterinary use, not a therapeutic good. Tesamorelin description in chemistry and drug-evaluation reviews as a growth hormone-releasing factor analogue is an identity statement for the reagent, not a conversion of the reagent into a registered product (PMID:21283099; PMID:22298602). Quotes that omit lot numbers, reuse a generic peptide template with no tesamorelin mass, or present branding without analytical data are not equivalent to a batch-linked package. Completeness of the CoA is the first filter; milligram price is the second.

How do local Australian stock and per-milligram analytical value change tesamorelin supplier comparisons?

Landed cost for an Australian laboratory is not an overseas list price. An untracked international consignment can arrive with a CoA lot code that does not match the vial, or with no chromatogram at all, after which analyst time is spent on identity work that should have been included in the purchase. Local Australian stock with tracked dispatch allows the laboratory to order against a published lot, receive the matching CoA, and schedule analytical work to a known arrival window. ClaraScience prices tesamorelin on that local-stock, tracked-dispatch and batch-documentation basis. GST treatment, an institutional purchase-order match, and a local pathway to query a lot-number mismatch are part of that landed-cost arithmetic even when they do not appear as a line on a foreign catalogue.

A practical comparison table has rows for HPLC purity and method, chromatogram supplied, observed mass versus theory, net peptide content, water and counter-ion, lot-number match between vial and CoA, related-substance reporting threshold, Australian stock and tracked dispatch, and research-use-only labelling. Divide quoted price by net peptide milligrams at the stated purity to obtain an analytical-value unit cost. A high HPLC-purity lot with low net peptide content can be more expensive per peptide milligram than a slightly lower HPLC-purity lot that includes documented net peptide content and a full mass spectrum. Red flags include missing lot numbers, purity without wavelength or column, mass spectrometry confirmed without m/z values, generic chromatograms, and any wording that implies human use.

Once identity, orthogonal HPLC and mass spectrometry, and net peptide content are in place, remaining tesamorelin price Australia differences largely reflect purification cut, documentation depth and whether the lot is already in Australian stock. The purchasing record should capture the specification first and the price second. That order of operations is how a research group avoids paying twice: once for the vial, and again in analyst hours to characterise an under-documented solid. Tesamorelin is a defined GHRF analogue in the evaluation literature; procurement should insist on the same definition on the CoA (PMID:17086939; PMID:19243281).

Order Tesamorelin with documentation

If this guide helped you evaluate Tesamorelin for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.

Open the Tesamorelin card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.

Frequently asked questions

Why does tesamorelin price Australia vary so much between listings?

Research-grade tesamorelin is a 44-residue N-hexenoylated GHRH analogue, so synthesis, preparative HPLC and identity testing cost more than for short peptides. Quotes also differ because some sellers price gross lyophilisate without net peptide content, water or counter-ion data, while others include a lot-linked HPLC and mass-spectrometry CoA. Compare the specification and the CoA completeness before comparing the milligram figure. Research use only.

Is HPLC area-percent enough to accept a tesamorelin quote?

No. HPLC area-percent without a method identifier, chromatogram, detection wavelength and lot match is incomplete. Intact-mass spectrometry, salt form and net peptide content or water convert that purity number into a characterised solid. Orthogonal HPLC and mass spectrometry is the minimum identity package for this analogue. A quote that cannot supply those fields is not comparable to a documented lot.

What is net peptide content and how does it affect unit cost?

Net peptide content is the peptide fraction of the lyophilised solid after counter-ion and residual water are accounted for, typically via amino-acid analysis or nitrogen content plus a counter-ion assay and Karl Fischer water. Gross milligram prices overstate peptide mass when acetate and water are high. Divide the quote by net peptide milligrams to compare lots on a true peptide basis.

Which CoA fields should match the vial before payment?

Product name, lot number, HPLC purity with method, observed mass and test date should appear on the CoA and reconcile to the vial label. The lot on the label must equal the lot on the CoA. Missing lot codes, generic chromatograms or a mass that does not match tesamorelin are grounds to withhold the purchase and request a complete batch file.

Is tesamorelin supplied for laboratory research only?

Yes. ClaraScience supplies tesamorelin as a laboratory research reagent with batch documentation, local Australian stock and tracked dispatch. It is not a therapeutic good and is not offered for human or veterinary use. Peer-reviewed evaluations that classify tesamorelin as a growth hormone-releasing factor analogue are cited here only to support chemical identity and nomenclature.

References

1. PMID:17086939 — Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor — Curr Opin Investig Drugs — 2006
2. PMID:19243281 — Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs — 2009
3. PMID:20554713 — Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data — J Clin Endocrinol Metab — 2010
4. PMID:21283099 — Tesamorelin — Nat Rev Drug Discov — 2011
5. PMID:22298602 — Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother — 2012

Research use only

This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.